August marks 25 years since basketball legend Sean Elliott received a #KidneyTransplant. From learning he had #KidneyDisease to his #transplant experience, he took the time to share his story with our CEO David-Alexandre "DA" Gros, M.D. The discussion highlights his efforts to stay healthy, the urgent need for new solutions to help reduce the #OrganTransplant waiting list, and his support for research that can lead to better options in #immunosuppression. Hear his inspiring story: https://lnkd.in/ewdYBEVZ
Eledon Pharmaceuticals, Inc.
Pharmaceutical Manufacturing
Irvine, California 2,320 followers
Targeting the CD40L pathway to develop potential therapies for organ and cell transplantation, autoimmune conditions.
About us
Eledon Pharmaceuticals is a clinical stage biotechnology company with immunology expertise that is developing therapies to protect and prevent rejection of transplanted organs, as well as to treat amyotrophic lateral sclerosis (ALS). The Company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand (also called “CD154”), a well-validated biological target with broad therapeutic potential.
- Website
-
https://eledon.com
External link for Eledon Pharmaceuticals, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 11-50 employees
- Headquarters
- Irvine, California
- Type
- Public Company
- Founded
- 2020
Locations
-
Primary
19900 MacArthur Blvd
550
Irvine, California 92612, US
-
78 Blanchard Rd
Burlington, Massachusetts 01803, US
Employees at Eledon Pharmaceuticals, Inc.
-
David-Alexandre "DA" Gros
Chief Executive Officer & Director at Eledon Pharmaceuticals
-
Ted Chan
Intellectual Property Leader | Patent Strategy | Trusted C-Suite Advisor | Life Sciences
-
Brooke Hegarty
Director Clinical Operations at Eledon
-
June Lee, MD FACCP
Biotech executive, Company Builder, Board Director, Investor
Updates
-
Our team includes experts in #immunology who are leveraging their significant knowledge of the CD40L pathway to develop novel therapies with the potential to protect transplanted organs and prevent rejection. Read more about our science here: https://lnkd.in/epuGENCp
-
-
We are pleased to announce the enrollment of the 80th participant in our ongoing Phase 2 BESTOW clinical trial assessing a treatment for the prevention of rejection in #KidneyTransplantation. This strong progress reflects the urgency for innovative solutions to address the unmet needs in #immunosuppression for #KidneyTransplant recipients. For details, see our press release: https://lnkd.in/eyju-yUH
-
-
Stories from the #transplant community drive our efforts to advance #immunosuppression research focused on the potential to extend the functional life of transplanted organs. When Chazley bravely shared her #KidneyHealth issues with her classmates, her professor was inspired to register as a living donor – a decision that would ultimately change both their lives: https://lnkd.in/gCEKAic5 Donate Life America
-
Waiting lists for #KidneyTransplants continue to grow longer, making the need for new #immunosuppressant solutions to support #OrganTransplant function and longevity increasingly urgent. The National Kidney Foundation shares insights on challenges to overcome in #KidneyTransplantation to achieve #TransplantsForAll: https://lnkd.in/gRnxcHgj
Transplantation
kidney.org
-
Guided by our mission to achieve #OneTransplantForLife, we initiated our Phase 2 BESTOW clinical trial to support innovative research focused on the potential to increase #KidneyTransplant function and longevity. Learn more: https://bestowstudy.com/
-
-
We are dedicated to supporting the health of people who need an #OrganTransplant. Learn more about our focus on developing new therapeutic solutions in #immunosuppression that may help preserve and protect transplanted kidneys: https://lnkd.in/eAEnPQEq
-
-
We believe that the development of new therapeutic approaches in #immunosuppression is a key factor to help address the critical organ shortage crisis. In this Men’s Health Magazine article, former professional basketball player Nate Robinson shares the challenges he has faced as one of the estimated 100,000 people in the U.S. on the #KidneyTransplant waiting list: https://lnkd.in/eMWAZ_7y
Nate Robinson's Fight for His Life
menshealth.com
-
For more than three decades, the Transplant Life Foundation has hosted the Transplant Games of America to celebrate the strength of #transplant recipients and honor the legacy of living donors through a series of exciting competitions and educational programs. As we work to advance research in #immunosuppressant solutions that may help increase transplant function and longevity, we are pleased to spotlight this special event dedicated to raising awareness of the most important issues affecting the transplant community. Watch highlights from the 2024 Transplant Games of America here: https://lnkd.in/gdV-tSxK
-
-
Innovation in #immunosuppression is crucial to drive the development of therapies that can potentially support the function and longevity of #OrganTransplants. In this interview with WBUR, experts in #transplant medicine discuss key issues related to the current landscape of immunosuppressant research and drug development: https://lnkd.in/gVPFTms5 We are focused on advancing research in #immunosuppressant solutions that may help support the prevention of rejection in #OrganTransplantation. See our press release to learn more about the latest updates from our Phase 1b clinical trial in #KidneyTransplantation: https://lnkd.in/eqmh72JV NPR American Society of Transplant Surgeons
Organ transplant patients are concerned about the lack of drug development in transplantation. Hear from ASTS member Kenneth Newell, MD, PhD, and William Fitzsimmons of Transplant Therapeutics Consortium, who were featured TODAY on NPR: https://lnkd.in/gVPFTms5
Has drug development in transplantation been stymied?
wbur.org